ISRCTN00049084
Completed
Not Applicable
A double blind randomised cross-over trial to assess the value of screening an adult population for hypothyroidism
Queen Mary University of London (UK)0 sites60 target enrollmentFebruary 10, 2009
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Primary hypothyroidism
- Sponsor
- Queen Mary University of London (UK)
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Women aged from 35 \- 79 years, men aged from 65 \- 79 years
- •2\. Attended general screening at BUPA Wellness Centres between 1 January 2006 and 15 September 2007
- •3\. Detected with thyroid stimulating hormone (TSH) greater than 4\.0 mU/
Exclusion Criteria
- •1\. People under current clinical surveillance for thyroid disease, or taking thyroxine, or having known pituitary or adrenal disease
- •2\. People known to have coronary artery disease
- •3\. People with any illness that in the doctor's opinion warranted exclusion from the trial
- •4\. Diabetics taking insulin or oral hypoglycaemics, or people taking anticoagulants (warfarin or phenindinone)
- •5\. People taking certain drugs that affect the serum concentration of TSH or free thyroxine
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Double blind randomised cross-over trial to assess the value of screening an adult population for hypothyroidism - CROSS OVER RANDOMISED TRIAL OF ADULT HYPOTHROIDISM SCREENINGEUCTR2005-003464-30-GBQueen Mary, University of London
Completed
Not Applicable
A randomised double-blinded cross-over trial comparing betamethasone valerate and tacrolimus ointment for the treatment of moderate to severe atopic eczemaISRCTN27411543Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)100
Completed
Not Applicable
A study to assess the effect of coffee on the ability to perform simple physical and mental exercises in healthy individuals during the post-lunch periodCTRI/2019/02/017763Dr Suganthi S16
Not yet recruiting
Not Applicable
EFFECT-FD: Effect of adding bezaFibrate to standard lipid lowering therapy on non-Fasting CholesTerol in patients with FamilialDysbetalipoproteinemiaFamilial Dysbetalipoproteinemia Familiaire Dysbetalipoproteinemie (dutch)NL-OMON29530niversity Medical Center Utrecht20
Completed
Phase 4
A randomized, double blind, cross-over trial to study the effects of adding bezafibrate to standard lipid lowering therapy on postprandial lipids in patients with Familial Dysbetalipoproteinemia <br>Familial DysbetalipoproteinemiaFredrickson Type III hyperlipoproteinemia10013317NL-OMON43954Academisch Medisch Centrum15